NEW YORK, July 21, 2021 /PRNewswire/ -- Mirimus, Inc., a
pioneer in RNAi therapeutic design and CRISPR/Cas9 gene editing
technology implementation, today announced a strategic
collaboration with Biogen Inc. (NASDAQ: BIIB) focused on the
development of RNAi-based therapeutics targeting multiple,
undisclosed neurological disease indications. Terms of the
collaboration between Mirimus and Biogen are undisclosed.
Mirimus was established in 2010 with the goal of creating a
scalable and cost-effective pipeline for model generation and
therapeutic development by harnessing the power of RNAi and CRISPR
technologies, including development of animal models crucial for
preclinical evaluation of new therapeutics. Under the agreement,
Mirimus will apply its expertise to engineer RNAi-based
therapeutics that will be assessed by Biogen to determine
feasibility in potential neurological disease settings. If
feasibility is established, the companies will have the option to
pursue pre-clinical development of the asset(s).
"We are proud to announce our collaboration with Biogen, a
highly respected pioneer in neuroscience," said Prem Premsrirut,
M.D., Ph.D., Co-founder and CEO of Mirimus. "This collaboration
marks an important advance for Mirimus as we seek to extend our
expertise in RNAi animal models to the development of RNAi-based
biotherapeutics. At our core, Mirimus' strength is applying our
scientific capabilities to solve complex medical issues, whether
that is identifying a new treatment paradigm for a neurological
disorder, as in the case with Biogen, or developing a game-changing
saliva-based, pooled PCR testing platform to quickly and accurately
isolate COVID-19 hotspots before they can become outbreaks. The
greater the challenge, the more excited we are at Mirimus."
About Mirimus, Inc.
Mirimus, Inc. was established in
2010 with the goal of creating a scalable and cost-effective
pipeline for model generation by harnessing the power of RNAi and
CRISPR technologies to develop animal models which are crucial for
preclinical evaluation of new therapeutics. Through cutting edge
technology, powerful predictive tools, and vital partnerships,
Mirimus is paving the path to develop safer and more effective
therapeutics by pin-pointing potential toxicities, validation, and
disease modeling. Since its founding, Mirimus has established
itself as a leader in conducting high-volume, complex and highly
effective PCR testing. This unique skillset led Mirimus to
develop SalivaClear, a COVID-19 testing platform that combines
saliva-based sampling, pooled testing and PCR diagnostics to
improve the scalability, efficiency, cost-effectiveness and
accuracy of COVID-19 testing. For more information, please visit
www.mirimus.com and www.salivaclear.com.
Media Contacts:
Tiberend Strategic Advisors,
Inc.
Johanna Bennett & Ingrid Mezo
jbennett@tiberend.com / 1-212-375-2686
imezo@tiberend.com / 1-646-604-5150
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mirimus-inc-forms-strategic-collaboration-with-biogen-to-develop-rnai-based-therapeutics-for-neurological-disease-indications-301338149.html
SOURCE Mirimus, Inc.